132858-47-0

Usage

Uses

Used in Pharmaceutical Applications:
1-(3,4-dimethoxyphenyl)-3-methylbutan-1-one is used as an anti-inflammatory agent for its ability to alleviate inflammatory and immune-related conditions. Its anti-inflammatory properties make it a promising candidate for the treatment of various diseases and disorders.
Used in Skincare Applications:
In the skincare industry, 1-(3,4-dimethoxyphenyl)-3-methylbutan-1-one is used as an antioxidant and anti-aging ingredient for its potential to protect the skin from oxidative stress and promote a youthful appearance.
Used in Neurodegenerative Disease Treatment:
1-(3,4-dimethoxyphenyl)-3-methylbutan-1-one is used as a neuroprotective agent for its potential to treat neurodegenerative diseases such as Alzheimer's and Parkinson's, due to its ability to protect neurons and slow down the progression of these conditions.

Upstream product

• 503-74-2 3-methylbutyric acid 
• 91-16-7 1,2-dimethoxybenzene 
• 108-12-3 isopentanoyl chloride 

Downstream Products

• 1381862-17-4 C₁₆H₂₂O₃ 
• 1381862-25-4 C₁₇H₂₂O₅ 
• 100523-44-2 2-isopentyl-4,5-dimethoxy-benzenesulfonic acid amide 
• 362467-67-2 7-(3'-methylbutyl)benzo[b][1,4]dioxepin-3-one 
• 2525-09-9 4-isopentyl-pyrocatechol 
• 108996-61-8 1,2-dimethoxy-4-(3-methylbutyl)benzene 

Relevant academic research and scientific papers

DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS

Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A)

The invention relates to compounds of the formula or a pharmaceutically acceptable salt thereof, wherein R′, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.

SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A)

The invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R', R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.

A new approach to the synthesis of peptidomimetic renin inhibitors: Palladium-catalyzed asymmetric allylation of acyclic alkyl aryl ketones

A new approach to the synthesis of Tekturna, a recently marketed drug for hypertension, takes advantage of a modified protocol of the Stoltz palladium-catalyzed asymmetric allylation with a t-BuPHOX ligand for the synthesis of allylated acyclic alkyl aryl

Conception, characterization and correlation of new marine odorants

Via a synthetic sequence consisting of PPA-mediated Friedel-Crafts acylation of veratrol (8), Clemmensen reduction, demethylation with TMSI, Williamson ether synthesis employing 3-chloro-2-(chloromethyl)prop-1-ene and in-situ ruthenium tetroxide oxidation, numerous substituted benzo[b][1,4]dioxepinones 15-27 and 2,3-dihydro-1H-5,9-di-oxacyclohepta[f]indenones 7, 13 and 14 were prepared to study their odor-structure correlation. In the course of these studies, we discovered the extremely powerful new marine odorant 7-(3′ -methylbutyl)benzo[b][1,4]dioxepin-3-one (16). On the basis of the measured odor threshold data, an olfactophore model was constructed that rationalizes the observed odor intensities, and indicates an aliphatic hydrophobe at a distance of 6.3 A from the centre of the aromatic-ring binding site. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003.